Sight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 20,487 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 20,487 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $5.98, for a total value of $122,512.26. Following the completion of the transaction, the insider now directly owns 685,381 shares in the company, valued at approximately $4,098,578.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Matthew Link also recently made the following trade(s):

• On Monday, October 21st, Matthew Link sold 21,831 shares of Sight Sciences stock. The shares were sold at an average price of $5.61, for a total transaction of $122,471.91.
• On Wednesday, October 16th, Matthew Link sold 20,734 shares of Sight Sciences stock. The shares were sold at an average price of $5.91, for a total transaction of $122,537.94.

Sight Sciences Stock Down 7.5 %

Shares of Sight Sciences stock traded down $0.45 during trading hours on Monday, reaching $5.52. 225,198 shares of the company’s stock were exchanged, compared to its average volume of 193,711. The company has a 50 day moving average of $6.31 and a two-hundred day moving average of $6.30. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $8.45. The company has a current ratio of 11.01, a quick ratio of 10.50 and a debt-to-equity ratio of 0.33. The stock has a market cap of $277.71 million, a P/E ratio of -5.16 and a beta of 2.71.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The company had revenue of $21.37 million during the quarter, compared to the consensus estimate of $21.32 million. During the same period in the prior year, the business posted ($0.30) EPS. On average, sell-side analysts forecast that Sight Sciences, Inc. will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

Large investors have recently modified their holdings of the business. State Board of Administration of Florida Retirement System acquired a new stake in Sight Sciences in the 1st quarter valued at about $59,000. Steele Capital Management Inc. acquired a new stake in Sight Sciences in the 2nd quarter valued at about $67,000. SG Americas Securities LLC acquired a new stake in Sight Sciences in the 3rd quarter valued at about $75,000. The Manufacturers Life Insurance Company acquired a new stake in Sight Sciences in the 2nd quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Sight Sciences by 51.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after purchasing an additional 9,106 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SGHT has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Citigroup upped their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a research report on Wednesday, July 10th. Lake Street Capital assumed coverage on shares of Sight Sciences in a research report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Morgan Stanley increased their target price on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.25.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.